Hangzhou Biotest Biotech Co.,Ltd. (688767.SS)
CNY 32.67
(0.28%)
CNY 32.67
(0.28%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 158.82 Million CNY | -15.93% |
| 2022 | 188.92 Million CNY | -41.58% |
| 2021 | 323.35 Million CNY | 69.39% |
| 2020 | 190.89 Million CNY | 125.92% |
| 2019 | 84.49 Million CNY | 49.6% |
| 2018 | 56.48 Million CNY | 17.96% |
| 2017 | 47.88 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 150.95 Million CNY | 6.56% |
| 2024 Q1 | 153.17 Million CNY | -3.56% |
| 2024 Q2 | 141.66 Million CNY | -7.51% |
| 2023 Q4 | 158.82 Million CNY | 20.89% |
| 2023 FY | 158.82 Million CNY | -15.93% |
| 2023 Q3 | 131.37 Million CNY | -2.0% |
| 2023 Q2 | 134.05 Million CNY | -13.4% |
| 2023 Q1 | 154.79 Million CNY | -18.06% |
| 2022 Q3 | 311.33 Million CNY | -29.36% |
| 2022 Q2 | 440.72 Million CNY | -24.05% |
| 2022 Q1 | 580.25 Million CNY | 79.45% |
| 2022 FY | 188.92 Million CNY | -41.58% |
| 2022 Q4 | 188.92 Million CNY | -39.32% |
| 2021 Q3 | 323.91 Million CNY | -14.54% |
| 2021 FY | 323.35 Million CNY | 69.39% |
| 2021 Q4 | 323.35 Million CNY | -0.17% |
| 2021 Q1 | 300.54 Million CNY | 57.44% |
| 2021 Q2 | 379.01 Million CNY | 26.11% |
| 2020 Q4 | 190.89 Million CNY | 0.0% |
| 2020 Q2 | 180.36 Million CNY | 0.22% |
| 2020 FY | 190.89 Million CNY | 125.92% |
| 2020 Q1 | 179.97 Million CNY | 0.0% |
| 2019 FY | 84.49 Million CNY | 49.6% |
| 2018 FY | 56.48 Million CNY | 17.96% |
| 2017 FY | 47.88 Million CNY | 0.0% |